Gilead Sciences Company Insiders

GILD Stock  USD 67.75  0.32  0.47%   
About 91 percent of Gilead Sciences' insiders are activelly selling. The analysis of the overall insider sentiment regarding Gilead Sciences suggests that quite a large number of insiders are panicking. Gilead Sciences employs about 18 K people. The company is managed by 42 executives with a total tenure of roughly 286 years, averaging almost 6.0 years of service per executive, having 428.57 employees per reported executive.
John Martin  Chairman
Chairman and CEO
Daniel ODay  Chairman
Chairman of the Board, CEO

Gilead Sciences' Insider Buying Vs Selling

9

 
Selling
 
Buying

Latest Trades

2024-04-01Merdad ParseyDisposed 2000 @ 72.96View
2024-02-28Merdad ParseyDisposed 2000 @ 73.18View
2024-01-16Andrew D DickinsonDisposed 5000 @ 85.78View
2024-01-09Johanna MercierDisposed 8242 @ 85.23View
2023-10-24Greg StantonDisposed @ 78.15
2023-10-17Andrew D DickinsonDisposed 5000 @ 80View
2023-09-26Greg StantonAcquired @ 75.53
2023-09-12Merdad ParseyDisposed 1501 @ 76.99View
2023-07-20Andrew D DickinsonDisposed 5000 @ 80View
2023-07-12Daniel S. GoldmanDisposed @ 76.38
2023-06-13Merdad ParseyDisposed 1485 @ 76.9View
Monitoring Gilead Sciences' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.

Acquired vs Disposed

Filed vs Not Filed

Insider sentiment refers to the collective sentiment or feeling of Gilead Sciences' insiders - typically its officers, directors, and beneficial owners holding more than a certain percentage of the company's stock - about the future prospects of Gilead Sciences. This sentiment is often gauged based on the trading activities of these insiders. If insiders are purchasing more shares of their own company, it may be interpreted as a bullish sentiment, indicating that they believe Gilead Sciences' stock will rise in value. Conversely, if insiders are selling shares, it might be seen as bearish, suggesting they expect the stock price to drop.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.

Gilead Sciences' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Gilead Sciences' future performance. Based on our forecasts, it is anticipated that Gilead will maintain a workforce of about 18000 employees by May 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Gilead Sciences' latest congressional trading

Congressional trading in companies like Gilead Sciences, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Gilead Sciences by those in governmental positions are based on the same information available to the general public.
2023-09-26Representative Greg StantonAcquired Under $15KVerify
2023-07-12Representative Daniel GoldmanDisposed $15K to $50KVerify
2022-01-13Senator Tommy TubervilleAcquired Under $15KVerify
2021-12-21Senator Jerry MoranAcquired Under $15KVerify
2021-11-10Representative Carol Devine MillerDisposed $15K to $50KVerify
2021-01-21Representative Marjorie Taylor GreeneAcquired Under $15KVerify
2020-12-22Representative Gilbert CisnerosDisposed Under $15KVerify
2020-12-18Representative Dean PhillipsDisposed Under $15KVerify
2020-09-01Representative Ed PerlmutterDisposed Under $15KVerify
2020-07-08Representative Roger W. MarshallDisposed Under $15KVerify
2020-06-29Representative William R. TimmonsDisposed Under $15KVerify
2020-02-20Representative Mikie SherrillDisposed Under $15KVerify
2019-10-25Representative Earl BlumenauerAcquired Under $15KVerify
2019-09-19Representative Bill FloresAcquired Under $15KVerify
2019-03-11Senator Shelley Moore CapitoAcquired Under $15KVerify
2018-04-23Senator Angus S. King, Jr.Acquired Under $15KVerify
2018-02-22Senator James M. InhofeAcquired $50K to $100KVerify
2017-09-20Senator Sheldon WhitehouseAcquired Under $15KVerify
2017-03-02Senator Susan M. CollinsAcquired Under $15KVerify
2014-04-14Senator Susan M CollinsAcquired Under $15KVerify

Gilead Sciences Management Team Effectiveness

The company has return on total asset (ROA) of 0.0978 % which means that it generated a profit of $0.0978 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2554 %, meaning that it created $0.2554 on every $100 dollars invested by stockholders. Gilead Sciences' management efficiency ratios could be used to measure how well Gilead Sciences manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.22. The current year's Return On Capital Employed is expected to grow to 0.19. At present, Gilead Sciences' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 5.9 B, whereas Total Current Assets are forecasted to decline to about 10.8 B.
The current year's Common Stock Shares Outstanding is expected to grow to about 1.5 B, whereas Net Income Applicable To Common Shares is forecasted to decline to about 4.9 B.

Gilead Sciences Workforce Comparison

Gilead Sciences is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 551,600. Gilead Sciences holds roughly 18,000 in number of employees claiming about 3% of equities under Health Care industry.

Gilead Sciences Profit Margins

The company has Profit Margin (PM) of 0.21 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.42 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.42.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin1.070.7799
Significantly Up
Pretty Stable

Gilead Sciences Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gilead Sciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gilead Sciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Gilead Sciences insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-03-01
1.3333
36
27
 1,266,642 
 267,582 
2023-12-01
0.5333
8
15
 18,447 
 31,737 
2023-09-01
0.5263
10
19
 38,304 
 60,680 
2023-06-01
1.6923
22
13
 112,501 
 38,058 
2023-03-01
1.25
40
32
 1,128,676 
 266,434 
2022-12-01
0.4762
10
21
 36,382 
 88,490 
2022-09-01
0.5
8
16
 16,694 
 80,872 
2022-06-01
1.625
39
24
 299,224 
 63,903 
2022-03-01
1.2571
44
35
 1,633,427 
 229,097 
2021-12-01
0.8333
5
6
 9,450 
 12,612 
2021-09-01
1.1429
8
7
 23,658 
 41,537 
2021-06-01
2.4
24
10
 168,644 
 74,893 
2021-03-01
1.2727
42
33
 1,402,589 
 189,827 
2020-12-01
1.1818
13
11
 53,390 
 49,439 
2020-09-01
0.8571
6
7
 13,446 
 19,331 
2020-06-01
1.28
32
25
 131,108 
 91,601 
2020-03-01
0.8571
48
56
 947,653 
 442,930 
2019-12-01
0.48
12
25
 211,478 
 343,962 
2019-09-01
1.0
7
7
 191,617 
 26,356 
2019-06-01
1.3913
32
23
 178,370 
 97,544 
2019-03-01
2.7692
36
13
 929,034 
 83,253 
2018-12-01
0.625
10
16
 558,351 
 725,117 
2018-09-01
0.75
9
12
 155,008 
 304,469 
2018-06-01
0.7083
34
48
 457,671 
 1,147,635 
2018-03-01
0.9298
53
57
 1,234,973 
 909,350 
2017-12-01
0.5172
15
29
 492,516 
 994,620 
2017-09-01
0.6471
22
34
 425,338 
 1,019,734 
2017-06-01
1.5882
27
17
 339,440 
 487,336 
2017-03-01
1.5385
40
26
 1,350,400 
 687,274 
2016-12-01
0.3214
9
28
 435,518 
 1,405,006 
2016-09-01
0.5806
18
31
 1,298,480 
 2,019,883 
2016-06-01
0.875
42
48
 896,658 
 1,544,093 
2016-03-01
1.2424
41
33
 1,551,153 
 1,165,038 
2015-12-01
0.3625
29
80
 1,055,327 
 2,145,346 
2015-09-01
0.4167
30
72
 1,263,033 
 2,600,238 
2015-06-01
0.6897
60
87
 1,071,786 
 2,039,036 
2015-03-01
0.6944
50
72
 2,155,801 
 2,132,415 
2014-12-01
0.3488
30
86
 1,099,268 
 2,489,076 
2014-09-01
0.4118
28
68
 850,943 
 1,710,788 
2014-06-01
0.7742
48
62
 776,261 
 1,389,602 
2014-03-01
0.6269
42
67
 1,189,150 
 1,990,741 
2013-12-01
0.32
8
25
 523,826 
 1,389,573 
2013-09-01
0.65
26
40
 888,373 
 1,771,840 
2013-06-01
1.4091
31
22
 2,552,914 
 2,599,503 
2013-03-01
0.6875
11
16
 327,177 
 462,178 
2012-12-01
0.575
23
40
 744,171 
 1,268,288 
2012-09-01
0.6667
22
33
 491,253 
 568,788 
2012-06-01
2.6667
32
12
 142,089 
 44,794 
2012-03-01
0.9091
20
22
 514,883 
 374,311 
2011-12-01
0.8333
5
6
 201,000 
 15,566 
2011-09-01
1.0
7
7
 26,671 
 22,736 
2011-06-01
2.3077
30
13
 164,938 
 47,570 
2011-03-01
1.1667
14
12
 587,746 
 62,706 
2010-12-01
0.4545
5
11
 126,000 
 246,747 
2010-09-01
3.5
7
2
 173,873 
 154,000 
2010-06-01
8.0
32
4
 191,503 
 15,100 
2010-03-01
1.0
18
18
 419,444 
 307,236 
2009-12-01
0.5625
9
16
 185,000 
 355,520 
2009-09-01
0.9091
20
22
 501,469 
 907,765 
2009-06-01
1.3158
25
19
 442,080 
 626,500 
2009-03-01
0.7917
19
24
 630,200 
 697,742 
2008-12-01
0.5556
15
27
 536,850 
 831,037 
2008-09-01
0.375
15
40
 667,528 
 853,200 
2008-06-01
0.156
22
141
 702,213 
 759,587 
2008-03-01
0.1391
21
151
 881,400 
 732,627 
2007-12-01
0.0412
7
170
 343,000 
 718,550 
2007-09-01
0.1765
9
51
 420,000 
 476,000 
2007-06-01
0.2
18
90
 612,696 
 823,592 
2007-03-01
0.1868
17
91
 683,000 
 516,920 
2006-12-01
0.0839
12
143
 446,600 
 786,670 
2006-09-01
0.0885
10
113
 282,381 
 551,792 
2006-06-01
0.4815
13
27
 398,750 
 314,500 
2006-03-01
0.2466
18
73
 781,500 
 633,710 
2005-12-01
0.1772
14
79
 370,386 
 665,776 
2005-09-01
0.5652
13
23
 463,562 
 509,704 
2005-06-01
0.1702
24
141
 1,081,672 
 954,662 
2005-03-01
0.6471
11
17
 652,296 
 402,889 
2004-12-01
0.4516
14
31
 628,064 
 665,566 
2004-09-01
0.4074
11
27
 140,993 
 259,120 
2004-06-01
1.5556
14
9
 249,353 
 164,000 
2004-03-01
0.8462
22
26
 542,500 
 268,515 
2003-12-01
0.3333
5
15
 212,000 
 311,500 
2003-09-01
0.3284
22
67
 361,457 
 609,258 
2003-06-01
1.0
2
2
 716.00 
 33,880 

Gilead Sciences Notable Stakeholders

A Gilead Sciences stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Gilead Sciences often face trade-offs trying to please all of them. Gilead Sciences' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Gilead Sciences' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
John MartinChairman and CEOProfile
Daniel ODayChairman of the Board, CEOProfile
Kathleen WatsonExecutive Vice President - Human ResourcesProfile
John McHutchisonExecutive Vice President - Clinical ResearchProfile
Andrew ChengExecutive Vice President - HIV Therapeutics and Development OperationsProfile
Andrew DickinsonExecutive Vice President - Corporate Development and StrategyProfile
William LeeExecutive Vice President - ResearchProfile
Martin SilversteinExecutive Vice President - StrategyProfile
Paul CarterExecutive Vice President - Commercial OperationsProfile
Diana BrainardSenior Vice President HIV and Emerging Viral InfectionsProfile
James MeyersExecutive Vice President - Worldwide Commercial OperationsProfile
Katie WatsonExecutive Vice President of Human ResourcesProfile
Jyoti MehraExecutive Vice President of Human ResourcesProfile
Laura HamillExecutive Vice President - Worldwide Commercial OperationsProfile
Taiyin YangExecutive Vice President - Pharmaceutical Development and ManufacturingProfile
Robin WashingtonCFO and Executive VPProfile
John MilliganPres and COOProfile
Kevin YoungCOOProfile
Brett PletcherExecutive VP and General CounselProfile
Gregg AltonExecutive VP of Corporate and Medical Affairs and SecretaryProfile
Norbert BischofbergerChief Scientific Officer and Executive VP of RandDProfile
Gayle WilsonIndependent DirectorProfile
Jacqueline BartonDirectorProfile
John MadiganIndependent DirectorProfile
Kevin LoftonIndependent DirectorProfile
Carla HillsIndependent DirectorProfile
John CoganLead Independent DirectorProfile
Nicholas MooreIndependent DirectorProfile
Kelly KramerDirectorProfile
Per WoldOlsenIndependent DirectorProfile
Harish ManwaniDirectorProfile
Etienne DavignonIndependent DirectorProfile
Richard WhitleyIndependent DirectorProfile
Sandra PattersonCorporate VPProfile
Michael QuigleyVP BiologyProfile
Linda HigginsInnovation ResearchProfile
Deborah TelmanGeneral AffairsProfile
Jacquie CFAVice RelationsProfile
Flavius MDExecutive ResearchProfile
Johanna MercierChief Commercial OfficerProfile
Diane WilfongCorp VPProfile
Rudolf ErtlCanada, AustraliaProfile

About Gilead Sciences Management Performance

The success or failure of an entity such as Gilead Sciences often depends on how effective the management is. Gilead Sciences management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Gilead management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Gilead management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets 0.21  0.22 
Return On Capital Employed 0.18  0.19 
Return On Assets 0.09  0.1 
Return On Equity 0.25  0.26 
The data published in Gilead Sciences' official financial statements usually reflect Gilead Sciences' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Gilead Sciences. For example, before you start analyzing numbers published by Gilead accountants, it's critical to develop an understanding of what Gilead Sciences' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Gilead Sciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Gilead Sciences' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Gilead Sciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Gilead Sciences. Please utilize our Beneish M Score to check the likelihood of Gilead Sciences' management manipulating its earnings.

Gilead Sciences Workforce Analysis

Traditionally, organizations such as Gilead Sciences use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Gilead Sciences within its industry.

Gilead Sciences Manpower Efficiency

Return on Gilead Sciences Manpower

Revenue Per Employee1.5M
Revenue Per Executive645.6M
Net Income Per Employee311.8K
Net Income Per Executive133.6M
Working Capital Per Employee266.9K
Working Capital Per Executive114.4M
When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.
You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for Gilead Stock analysis

When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Stocks Directory
Find actively traded stocks across global markets
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.13)
Dividend Share
3
Earnings Share
4.5
Revenue Per Share
21.728
Quarterly Revenue Growth
(0.04)
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.